cancer

New research has identified 485 chemicals used in US pesticide products that are linked to breast cancer. The findings, reported by The Guardian, are raising concerns about consumer and worker exposure to common agricultural chemicals and prompting calls for tighter regulation and further safety review of pesticide ingredients.

AstraZeneca has invested $2bn in US biotech firm Summit Therapeutics as part of a major cancer research collaboration. The FTSE 100 drugmaker agreed to buy 109,000 shares in the Nasdaq-listed company at $18.36 per share, funding a tie-up aimed at developing new cancer treatments.

A new study shows that loss of parts of the Y chromosome, a change seen in many men as they age, can actively drive cancer development. Researchers report the missing genetic material affects tumour growth in men, offering a possible explanation for why certain cancers behave differently between the sexes.

Researchers report observing how an aggressive brain cancer physically remodels brain tissue as it grows, offering a live view of tumor progression. The findings shed light on how deadly brain tumors invade and distort surrounding structures, which could inform future treatment approaches. The work is drawing attention for its striking visualization of the disease's effects on the brain.

New reporting highlights that people who survived cancer in childhood face a significantly elevated risk of serious mental health difficulties in adulthood, including depression, anxiety and other psychiatric conditions. The findings point to long-term psychological effects of early cancer diagnosis and treatment, and renew calls for survivors to receive sustained mental health monitoring and support, not just physical follow-up care, well into their adult lives.

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes in dense cell populations strongly influence the best timing of treatment cycles, with implications for both cancer therapy and antibiotics. Treatment resistance remains one of the central challenges in medicine, and the findings suggest that timing could be adjusted based on how tightly cells pack together rather than on biology alone. The work points to new ways of scheduling therapies to delay or avoid resistance.

Coverage is circulating of the second part of a highlights roundup from the World Cancer Congress 2026, summarising key presentations and developments shared at the global oncology gathering. The roundup is aimed at cancer professionals and researchers following the congress remotely, distilling sessions into digestible takeaways. Interest centres on what new research, treatment approaches and policy discussions were featured at this year's event.

A new report outlines how biological research is changing the way breast cancer is diagnosed and treated. Understanding tumour biology is increasingly guiding treatment choices, moving care away from one-size-fits-all approaches toward therapies matched to the specific characteristics of each patient's cancer. The piece has drawn attention from clinicians and patient advocates following shifts in treatment standards.

Medical experts in Madison say artificial intelligence can detect signs of cancer that human clinicians are unable to see, offering a potentially powerful new tool in diagnosis. However, they caution that the technology has real limitations and is not a replacement for human judgment. The remarks highlight growing attention on AI's role in cancer screening and the need to understand where it falls short.

Researchers publishing in Communications Biology report that deletions and regulatory disruption of the Y chromosome recur across cancers, suggesting loss of this chromosome may play a functional role in tumour development rather than being a harmless byproduct. The findings add to growing interest in how sex chromosome instability shapes cancer risk and progression in men.

The World Cancer Congress 2026 is drawing attention with a roundup of its key moments and announcements. Coverage so far focuses on highlights from the global gathering of cancer researchers, clinicians and advocates, though specific findings or policy outcomes have not yet been detailed. Interest is expected to grow as sessions conclude and results are shared.

UF Health researchers report that cancer diagnoses in the United States drop sharply during holiday periods, while outcomes for patients diagnosed around those dates are worse. The findings suggest holiday disruptions delay screenings and follow-up care, allowing cancers to be caught at later, harder-to-treat stages, and raise questions about how seasonal healthcare patterns affect patient survival.

NPR has published the story of a professor who was diagnosed with lung cancer and underwent cutting-edge treatment, reportedly involving mRNA-based approaches and questions of affordability. The piece follows his shift from expert observer to patient navigating new therapies. It is drawing attention as a personal account of where lung cancer treatment stands and who can access it.

Biotech company Vyriad has begun the first-in-human clinical trial of VV169, an in vivo CAR T therapy that engineers immune cells inside the patient's body rather than in a lab. The early-stage trial marks a first step in testing the safety of the experimental cancer treatment in people, an approach watched closely as it could simplify a cell therapy process that is currently complex and costly.

Researchers have highlighted three previously overlooked RNA molecules as potential new markers for colorectal cancer. The findings suggest these molecules could help detect the disease earlier and guide treatment choices, offering a possible addition to existing screening and diagnostic tools. Colorectal cancer remains one of the most common cancers worldwide, so any lead on earlier detection is drawing scientific and media attention.

The Trump administration has committed more than $5 billion to a program called the Genesis Mission, aimed at advancing cancer research, semiconductor development, and quantum computing. The initiative signals a major federal investment in strategic technologies, combining health science goals with industrial policy on chips and next-generation computing capabilities.

A New York Times opinion piece asks why clinical trials for cancer drugs take so long, examining delays in the process of testing new treatments on patients. The article prompts discussion about whether trial design, regulatory requirements, or patient recruitment are the main bottlenecks in getting promising cancer therapies to people faster.